Siglec-15 promotes a feed-forward loop between TNBC cells and macrophages via the NF-κB/DcR3/CCL18/STAT3 axis.

Sizhang Wang, Hua Qi Wang, Hui Zhao, Ruixia Zhao, Peng Zhao, Qiang Mu

Abstract read

In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sizhang WangThe Second Department of General Surgery, Yangquan First People's Hospital, Yangquan, Shanxi, 045000, China.

Hua Qi WangQingdao Medical College of Qingdao University, Qingdao, Shandong, 266042, China.

Hui ZhaoDepartment of Breast surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, 266042, China.

Ruixia ZhaoDepartment of Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, Shandong, 266042, China. Electronic address: 17805325589@163.com.

Peng ZhaoDepartment of Molecular Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, Shandong, 266042, China. Electronic address: zhaopeng@uhrs.edu.cn.

Qiang MuDepartment of Breast surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, 266042, China. Electronic address: muqiang@qdu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

M2-like tumor-associated macrophages (TAMs), recognized as a significant risk factor in tumor progression, play a crucial role in the tumor microenvironment. While Sialic acid binding Ig like Lectin 15 (Siglec-15), an well-characterized immune-checkpoint inhibitor, has been demonstrated to impact immunotherapy response and tumor progression, its role in TMAs-mediated tumor progression remains largely unclear. In this study, we demonstrated that the high expression of Siglec-15 in triple-negative breast cancer (TNBC) acts as a pivotal driver of the interaction between tumor cells and macrophages. TNBC cells with overexpressed Siglec-15 can induce the polarization of macrophages into CC chemokine ligand 18 (CCL18)

Indexed as

CCL18DcR3Siglec-15Triple-negative breast cancerTumor-associated macrophages

Identifiers

PMID42759405

DOI10.1016/j.tranon.2026.103032

PMCPMC13625897

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.